TLR7 and psoriasis: In vivo evidence from murine models suggested that treating psoriatic lesions with a TLR7 agonist could shift macrophages to a higher M1/M2 ratio, where excessive stimulation of TLR7 was associated with psoriasis pathogenesis 87.